Peng-Peng Kuang1,2, Ning Li3, Zui Liu4, Tian-Yu Sun1, Shu-Quan Wang1, Jia Hu1, Wei Ou1, Si-Yu Wang1. 1. Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. 2. Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. 3. Department of Breast Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. 4. Division of Cardiac Surgery, Heart Center, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Abstract
BACKGROUND: Although adjuvant chemotherapy is established for patients with non-small-cell lung cancer (NSCLC), the long-term survival remains to be improved. Postsurgical circulating tumor DNA (ctDNA) analysis of resectable NSCLC may identify patients at high risk of recurrence after adjuvant chemotherapy and facilitate personalized therapy. METHODS: This analysis included 38 patients who underwent curative-intent resection and received adjuvant chemotherapy for NSCLC. ctDNA analyses of tumor tissue, and pre- and post-operative plasma samples were performed with next-generation sequencing targeting 425 cancer-relevant genes. We define a ctDNA positive event as at least one shared mutation identified simultaneously in the plasma and tumor specimens. The primary endpoint was recurrence-free survival (RFS). RESULTS: At least one somatic mutation was identified in the tumor tissue of all 38 patients. Tumor tissue-specific mutated ctDNA was detected in the preoperative plasma samples of 19 (50%) patients. ctDNA in preoperative plasma was in good accordance with that in tissue. ctDNA was detectable in the first post-operative pre-chemotherapy samples of 8 of 35 (22.9%) patients and was associated with inferior RFS (HR, 3.69; P = 0.033). ctDNA was detected in the first post-chemotherapy samples of 8 of 36 (22.2%) patients and was also associated with inferior RFS (HR, 8.76; P < 0.001). CONCLUSIONS: Postoperative and post-chemotherapy ctDNA is a promising prognostic marker for resected NSCLC. ctDNA analyses may define a subgroup that remains at high risk of relapse despite standard adjuvant chemotherapy, and may help to inform intensified therapeutic strategies.
BACKGROUND: Although adjuvant chemotherapy is established for patients with non-small-cell lung cancer (NSCLC), the long-term survival remains to be improved. Postsurgical circulating tumor DNA (ctDNA) analysis of resectable NSCLC may identify patients at high risk of recurrence after adjuvant chemotherapy and facilitate personalized therapy. METHODS: This analysis included 38 patients who underwent curative-intent resection and received adjuvant chemotherapy for NSCLC. ctDNA analyses of tumor tissue, and pre- and post-operative plasma samples were performed with next-generation sequencing targeting 425 cancer-relevant genes. We define a ctDNA positive event as at least one shared mutation identified simultaneously in the plasma and tumor specimens. The primary endpoint was recurrence-free survival (RFS). RESULTS: At least one somatic mutation was identified in the tumor tissue of all 38 patients. Tumor tissue-specific mutated ctDNA was detected in the preoperative plasma samples of 19 (50%) patients. ctDNA in preoperative plasma was in good accordance with that in tissue. ctDNA was detectable in the first post-operative pre-chemotherapy samples of 8 of 35 (22.9%) patients and was associated with inferior RFS (HR, 3.69; P = 0.033). ctDNA was detected in the first post-chemotherapy samples of 8 of 36 (22.2%) patients and was also associated with inferior RFS (HR, 8.76; P < 0.001). CONCLUSIONS: Postoperative and post-chemotherapy ctDNA is a promising prognostic marker for resected NSCLC. ctDNA analyses may define a subgroup that remains at high risk of relapse despite standard adjuvant chemotherapy, and may help to inform intensified therapeutic strategies.
Authors: P E Postmus; K M Kerr; M Oudkerk; S Senan; D A Waller; J Vansteenkiste; C Escriu; S Peters Journal: Ann Oncol Date: 2017-07-01 Impact factor: 32.976
Authors: Jillian Phallen; Mark Sausen; Vilmos Adleff; Alessandro Leal; Carolyn Hruban; James White; Valsamo Anagnostou; Jacob Fiksel; Stephen Cristiano; Eniko Papp; Savannah Speir; Thomas Reinert; Mai-Britt Worm Orntoft; Brian D Woodward; Derek Murphy; Sonya Parpart-Li; David Riley; Monica Nesselbush; Naomi Sengamalay; Andrew Georgiadis; Qing Kay Li; Mogens Rørbæk Madsen; Frank Viborg Mortensen; Joost Huiskens; Cornelis Punt; Nicole van Grieken; Remond Fijneman; Gerrit Meijer; Hatim Husain; Robert B Scharpf; Luis A Diaz; Siân Jones; Sam Angiuoli; Torben Ørntoft; Hans Jørgen Nielsen; Claus Lindbjerg Andersen; Victor E Velculescu Journal: Sci Transl Med Date: 2017-08-16 Impact factor: 17.956
Authors: B Lee; L Lipton; J Cohen; J Tie; A A Javed; L Li; D Goldstein; M Burge; P Cooray; A Nagrial; N C Tebbutt; B Thomson; M Nikfarjam; M Harris; A Haydon; B Lawrence; D W M Tai; K Simons; A M Lennon; C L Wolfgang; C Tomasetti; N Papadopoulos; K W Kinzler; B Vogelstein; P Gibbs Journal: Ann Oncol Date: 2019-09-01 Impact factor: 32.976
Authors: Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan Journal: Science Date: 2015-03-12 Impact factor: 47.728
Authors: Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox Journal: Lancet Date: 2009-07-24 Impact factor: 79.321
Authors: Aadel A Chaudhuri; Jacob J Chabon; Alexander F Lovejoy; Aaron M Newman; Henning Stehr; Tej D Azad; Michael S Khodadoust; Mohammad Shahrokh Esfahani; Chih Long Liu; Li Zhou; Florian Scherer; David M Kurtz; Carmen Say; Justin N Carter; David J Merriott; Jonathan C Dudley; Michael S Binkley; Leslie Modlin; Sukhmani K Padda; Michael F Gensheimer; Robert B West; Joseph B Shrager; Joel W Neal; Heather A Wakelee; Billy W Loo; Ash A Alizadeh; Maximilian Diehn Journal: Cancer Discov Date: 2017-09-24 Impact factor: 39.397
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Jeanne Tie; Joshua D Cohen; Bert Volgestein; Peter Gibbs; Yuxuan Wang; Lu Li; Michael Christie; Koen Simons; Hany Elsaleh; Suzanne Kosmider; Rachel Wong; Desmond Yip; Margaret Lee; Ben Tran; David Rangiah; Matthew Burge; David Goldstein; Madhu Singh; Iain Skinner; Ian Faragher; Matthew Croxford; Carolyn Bampton; Andrew Haydon; Ian T Jones; Christos S Karapetis; Timothy Price; Mary J Schaefer; Jeanne Ptak; Lisa Dobbyn; Natallie Silliman; Isaac Kinde; Cristian Tomasetti; Nickolas Papadopoulos; Kenneth Kinzler Journal: Gut Date: 2018-02-02 Impact factor: 23.059